Atogepant + Placebo for Atogepant
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Menstrual Migraine (MM)
Conditions
Menstrual Migraine (MM)
Trial Timeline
Feb 10, 2025 → Jul 1, 2027
NCT ID
NCT06806293About Atogepant + Placebo for Atogepant
Atogepant + Placebo for Atogepant is a phase 3 stage product being developed by AbbVie for Menstrual Migraine (MM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06806293. Target conditions include Menstrual Migraine (MM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06810505 | Phase 3 | Recruiting |
| NCT06806293 | Phase 3 | Recruiting |
| NCT06241313 | Phase 3 | Recruiting |
| NCT05861427 | Phase 3 | Completed |
Competing Products
11 competing products in Menstrual Migraine (MM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elagolix + Estradiol /norethindrone acetate (E2/NETA) | AbbVie | Phase 3 | 77 |
| Marvelon | Merck | Approved | 85 |
| paroxetine | Novo Nordisk | Approved | 84 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Rimegepant + Placebo Comparator + Standard of Care + Rimegepant | Pfizer | Phase 3 | 76 |
| Levonorgestrel/Ethinyl Estradiol | Pfizer | Phase 3 | 76 |
| Levetiracetam | UCB | Pre-clinical | 20 |
| Drospirenone and ethinyl estradiol + Placebo | Bayer | Pre-clinical | 20 |
| EE20/DRSP(YAZ, BAY86-5300) + Placebo | Bayer | Phase 3 | 74 |
| Vilaprisan (BAY1002670) | Bayer | Phase 3 | 74 |
| Etonogestrel 68mg implant | Organon | Phase 1 | 28 |